+

WO2002060373A3 - Derives indoliques et leur utilisation en tant qu'inhibiteurs de l'heparanase - Google Patents

Derives indoliques et leur utilisation en tant qu'inhibiteurs de l'heparanase Download PDF

Info

Publication number
WO2002060373A3
WO2002060373A3 PCT/IL2002/000080 IL0200080W WO02060373A3 WO 2002060373 A3 WO2002060373 A3 WO 2002060373A3 IL 0200080 W IL0200080 W IL 0200080W WO 02060373 A3 WO02060373 A3 WO 02060373A3
Authority
WO
WIPO (PCT)
Prior art keywords
indole derivatives
heparanase inhibitors
heparanase
diseases
inhibitors
Prior art date
Application number
PCT/IL2002/000080
Other languages
English (en)
Other versions
WO2002060373A2 (fr
Inventor
Maty Ayal-Hershkovitz
Daphna Miron
Ofra Levy
Original Assignee
Insight Strategy And Marketing
Maty Ayal-Hershkovitz
Daphna Miron
Ofra Levy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy And Marketing, Maty Ayal-Hershkovitz, Daphna Miron, Ofra Levy filed Critical Insight Strategy And Marketing
Priority to AU2002230056A priority Critical patent/AU2002230056A1/en
Publication of WO2002060373A2 publication Critical patent/WO2002060373A2/fr
Publication of WO2002060373A3 publication Critical patent/WO2002060373A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés indoliques utilisés comme inhibiteurs de l'héparanase dans le traitement de maladies et de troubles dus ou liés à l'activité catalytique de l'héparanase, tels que le cancer, les maladies inflammatoires et les maladies auto-immunes.
PCT/IL2002/000080 2001-01-29 2002-01-29 Derives indoliques et leur utilisation en tant qu'inhibiteurs de l'heparanase WO2002060373A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002230056A AU2002230056A1 (en) 2001-01-29 2002-01-29 Indole derivatives and their uses as heparanase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26430701P 2001-01-29 2001-01-29
US60/264,307 2001-01-29

Publications (2)

Publication Number Publication Date
WO2002060373A2 WO2002060373A2 (fr) 2002-08-08
WO2002060373A3 true WO2002060373A3 (fr) 2003-03-20

Family

ID=23005456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000080 WO2002060373A2 (fr) 2001-01-29 2002-01-29 Derives indoliques et leur utilisation en tant qu'inhibiteurs de l'heparanase

Country Status (2)

Country Link
AU (1) AU2002230056A1 (fr)
WO (1) WO2002060373A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696231B2 (en) * 2001-10-30 2010-04-13 Laboratoires Serono Sa Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
EP2044026B1 (fr) * 2006-06-22 2014-03-26 Prana Biotechnology Limited Procédé de traitement d'une tumeur cérébrale gliome
AU2007312880A1 (en) * 2006-10-20 2008-04-24 The Australian National University Inhibition of degradation of extracellular matrix
CN104370799B (zh) * 2014-11-27 2017-07-21 天津坤健生物制药有限公司 一种3‑氧代肼基取代吲哚酮类衍生物及其制备方法与应用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107200A1 (fr) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Inhibiteurs d'héparanase et leur utilisation
EP3381906A1 (fr) 2017-03-27 2018-10-03 Leadiant Biosciences SA Composes utiles comme inhibiteurs d'heparanase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5919809A (en) * 1989-04-18 1999-07-06 Pfizer Inc. 3-substituted-2-oxindole derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5919809A (en) * 1989-04-18 1999-07-06 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby

Also Published As

Publication number Publication date
AU2002230056A1 (en) 2002-08-12
WO2002060373A2 (fr) 2002-08-08

Similar Documents

Publication Publication Date Title
WO2002060374A3 (fr) Derives de benz-1,3-azole et leurs utilisations en tant qu'inhibiteurs de l'heparanase
WO2005074375A3 (fr) Inhibiteurs de l'heparanase et utilisations
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2002060867A3 (fr) Derives de carbazole et leur utilisation en tant qu'inhibiteurs d'heparanase
WO2006078287A3 (fr) Inhibiteurs de pde4b
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005007141A3 (fr) Inhibiteurs de l'ubiquitine ligase et methodes associees
WO2005046603A3 (fr) Composes pyridiniques
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
WO2007050793A3 (fr) Methodes et compositions de traitement du syndrome de marfan et de troubles associes
WO2003080582A3 (fr) Derives de fredericamycine
WO2004103960A3 (fr) Composes et utilisations de ces derniers
NO20053384D0 (no) Benzazepinderivater for behandling av neurologiske forstyrrelser.
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
WO2005053609A3 (fr) Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
WO2002060375A3 (fr) Derives d'oxyde de diphenyle et leurs utilisations en tant qu'inhibiteurs de l'heparanase
WO2003088748A8 (fr) Utilisation d'heme-oxygenase-1 et produits de degradation d'heme
WO2004031105A3 (fr) Utilisation d'antigenes a33 et de jam-it
WO2001098279A3 (fr) Bis-arylsulfones
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
WO2005013911A3 (fr) Usages protecteurs et therapeutiques de tocotrienols

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载